BioSpace2h
Lilly’s Omvoh Beats J&J’s Stelara in Head-to-Head Phase III Crohn’s Disease Trial
At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...
optometryadvisor4h
Machine Learning Shows Promise in Assessing Psoriasis Severity
Machine learning models may be a useful tool for psoriasis severity assessment in clinical settings, despite a need for further research.
Managed Healthcare Executive4h
FDA Approves Imuldosa, the Fifth Stelara Biosimilar
Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.
Pharmabiz10h
US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx
US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx: Brussels, Belgium Tuesday, October 15, 2024, 13:00 Hrs [IST] UCB, a global biopharmaceutical compa ...
Drug Store News18h
FDA approves Dong-A ST’s Stelara biosimilar
Imuldosa is a biosimilar to Stelara, a blockbuster drug developed by Janssen Biotech for the treatment of patients with ...